Sartorius AG
Otto-Brenner-Str. 20
Phone: +49 5513080p:+49 5513080 GOETTINGEN, 37079  Germany Ticker: SRTSRT

Sartorius continues on its fast growth trajectory - significant double-digit increases in sales and earnings

GÖTTINGEN, Germany, July 21, 2021 /PRNewswire/ -- The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake1.


"In the first six months of the year, we have seen unabated high demand for innovative technologies used in the development and production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines and coronavirus test kits have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP–grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug development so that innovative therapies reach patients faster," said Executive Board Chairman and CEO Joachim Kreuzburg.

"Due to the ongoing expansion of our production facilities worldwide, we are well prepared to respond to the high demand expected to continue, and recruitment of additional employees is continuing at full speed. As communicated at the beginning of July, we significantly raised our sales and earnings forecast for the full year yet again though forecasts are currently subject to above-average uncertainty due to the various pandemic-related effects," emphasized Kreuzburg.

Business development of the Group

Based on constant currencies, Group sales revenue rose 60.1 percent to around 1,629 million euros (reported: +54.2 percent). The majority of this growth was generated based on the strong organic expansion of the core businesses of both divisions in all regions. Acquisitions2 added a good 8 percentage points to the increase in sales revenue, and the growth related to the development and production of vaccines and coronavirus test kits was about 22 percentage points. Order intake1 grew even more dynamically, rising to 2,179 million euros (+82.4 percent in constant currencies of which around 27 percentage points were attributable to the coronavirus pandemic and around 10 percentage points to acquisitions; reported: +75.0 percent).

In the first half, underlying EBITDA1 was up sharply by 89.2 percent to 555 million euros while the corresponding margin rose to 34.1 percent (H1 2020: 27.8 percent). The increase was supported especially by economies of scale and, additionally, by partially deferred cost development caused by the low number of business trips and underproportionate new hires in non–production areas due to the pandemic. These effects are expected to decrease as the year progresses. Relevant net profit1 for the Group grew by 108.7 percent to 259 million euros; earnings per ordinary share were 3.79 euros (H1 2020: 1.81 euros) and per preference share, 3.80 euros (H1 2020: 1.82 euros).

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for manufacturing biopharmaceuticals, kept up the strong pace seen at the beginning of the year and expanded in the first half of 2021 by 62.6 percent in constant currencies to 1,266 million euros (reported: +56.5 percent). The company's non–pandemic–related core business with manufacturers of biopharmaceutical medications performed particularly well. Beyond this, the ramp-up in coronavirus vaccine production by many manufacturers added around 26 percentage points to the increase in sales revenue. Non-organic growth contributed by the acquisitions2 closed in the prior year was a good 6 percentage points. Growth of the division benefited from expanded production capacities at several sites and from overall stable, yet strained supply chains.

The division's order intake increased even more strongly than its sales revenue, soaring 91.0 percent in constant currencies to 1,803 million euros (reported: +83.1 percent). Part of this higher order intake is due to the ordering patterns of some customers who in the current situation have been placing their orders further in advance than usual.

Underlying EBITDA1 of the Bioprocess Solutions Division rose by 86.2 percent to 460 million euros and thus at a significantly overproportionate rate in relation to sales. The respective margin climbed year over year from 30.5 percent to 36.3 percent. Economies of scale as well as a cost base that grew only slowly in some areas due to the pandemic contributed to this steep rise in profitability.

The Lab Products & Services Division, which specializes in equipment and technologies for life science research and pharmaceutical laboratories, saw sales revenue grow sharply in the first half of 2021 by 52.0 percent in constant currencies to 363 million euros (reported: +46.6 percent) compared to a prior-year period that was dampened by the pandemic. At 38 percentage points, the majority of the increase in sales revenue in the first six months of 2021 was organic, while non-organic growth was around 14 percentage points. Components used in coronavirus test kits accounted for about 9 percentage points of organic growth. Development was especially dynamic in the strategic growth area of bioanalytical instruments, which Sartorius had built up over the past years by making three acquisitions in total.

Order intake grew at a similar strong pace as sales revenue, up 49.9 percent in constant currencies to 375 million euros (reported: +44.5 percent).

Underlying EBITDA1 of the Lab Products & Services Division rose very significantly in the first half of 2021 by 105.1 percent from 46 million euros in the prior-year first half to 95 million while the corresponding margin reached 26.2 percent (H1 2020: 18.7 percent). This margin expansion was based on economies of scale, positive development of the product mix, and cost development that was underproportionate in some areas due to the pandemic.

Business development in the regions

Sartorius increased its revenues very significantly in all three business regions. Sales revenue in the EMEA3 region that contributes the highest share of around 42 percent to total Group revenue amounted to 683 million euros, up 63.8 percent in constant currencies (reported: +62.7 percent). The Americas region accounted for about 32 percent of total Group sales. Here, business grew by 52.0 percent to 519 million euros in constant currencies (reported: +39.1 percent). Sales in the Asia | Pacific region likewise saw dynamic growth, up 65.5 percent in constant currencies to 428 million euros (reported: +61.9 percent). As a result, this region's share of total Group revenue was 26 percent.

Key financial indicators

The Sartorius Group has a very sound balance sheet and financial base. At the end of the first half, the equity ratio stood at 31.3 percent (December 31, 2020: 29.9 percent). Net debt to underlying EBITDA1 was 1.8 on the reporting date, relative to 2.6 at year-end 2020. The ratio of capital expenditures (CAPEX) to sales in the first half of 2021 was 9.0 percent relative to 8.5 percent in the year-earlier period. Overall cash flow from investing activities rose in the reporting period by 71.3 percent, amounting to –159.9 million euros.

Substantial increase in the number of employees

As of June 30, 2021, the Sartorius Group employed a total of 11,981 people worldwide. Compared with December 31, 2020, headcount thus rose considerably by 1,344 or around 12.6%. The higher increase in the number of employees compared with previous years is especially attributable to the expansion of production capacities that was moved ahead of schedule and accelerated to some extent. However, due to the pandemic, buildup of the workforce was underproportionate on the whole compared with the company's business development. This trend particularly affected the non-production departments, such as sales and marketing functions, and is expected to subside as a result of additional hires during the further course of the year.

Forecast for the full year of 2021 raised

Based on the dynamic business performance in the first half, strong order intake, and on expanded production capacities, management raised its full-year growth forecast again at the beginning of July for fiscal 2021. Accordingly, the Sartorius Group projects consolidated sales growth of around 45 percent (previously around 35 percent) and an underlying EBITDA margin1 of about 34 percent (previously about 32 percent). For the Bioprocess Solutions Division, sales are anticipated to increase by about 50 percent (previously about 40 percent), and the underlying EBITDA margin1 is projected at around 36 percent (previously around 34 percent). Sales growth for the Lab Products & Services Division is expected to be around 30 percent (previously around 20 percent) at an underlying EBITDA margin1 of about 26 percent (previously about 24 percent).

The investment program for 2021 is to remain unchanged at around 400 million euros. Due to the sales revenue that is now expected to be higher, the corresponding CAPEX ratio for the Group is projected at about 12 percent (previously about 14%). The focus of the substantial investments is on the partly extended and accelerated expansion of production capacities, primarily at sites in Germany, Puerto Rico, China, and South Korea. Net debt to underlying EBITDA1 is expected to be slightly below 2.0 at year-end (previously about 2.0). Possible acquisitions are not included in these projections.

Mid-range targets updated in January 2021 remain unchanged and assume that for 2025, consolidated sales revenue will increase to about 5 billion euros at an underlying EBITDA margin of around 32 percent.

All forecasts are based on constant currencies as in the past years. In addition, the company assumes that the global economy will increasingly recover as the current year progresses and that supply chains will remain stable.

Financial indicators of the comparative period partly restated due to the finalized purchase price allocation of acquisitions made in 2020.

1 Sartorius publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.

  • Order intake: all customer orders contractually concluded and booked during the respective reporting period
  • Underlying EBITDA: earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
  • Relevant net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and the normalized tax rate
  • Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period

2 Acquisitions of selected life science businesses from Danaher; BIA Separations; and of WaterSep BioSeparations

3 EMEA = Europe, Middle East, Africa 

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

Follow Sartorius onTwitter @Sartorius_Group and on LinkedIn.

Conference call
Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG, and Rainer Lehmann, CFO and a member of the Executive Board, will discuss the company's business results with analysts and investors on July 21, 2021, at 3:30 p.m. Central European Summer Time (CEST) in a teleconference. You may register by clicking on the following link:

The presentation will be available on the same day starting at 3:15 p.m. CEST, for viewing on our website at:

Current image files

Financial calendar
October 20, 2021                                Publication of nine-month figures (January to September 2021)


Key performance indicators for the first half of 2021

Sartorius Group

Bioprocess Solutions

Lab Products & Services

in millions of € unless
otherwise specified

6-mo. 2021

6-mo. 20201

Δ in %

Δ in % cc2

6-mo. 2021

6-mo. 20201

Δ in %

Δ in % cc2

6-mo. 2021

6-mo. 20201

Δ in %

Δ in % cc2

Sales revenue and order intake

Order intake













Sales revenue













-  EMEA3


























Asia | Pacific3
























EBITDA margin4 in %







Net profit5




Financial data per share

per ordinary share5 in €




per preference share5 in €




June 30, 2021

Dec. 31, 20201

Balance sheet | financials

Balance sheet total






Equity ratio in %



Net debt



Net debt to underlying EBITDA



1 The previous year's figures have been restated due to finalization of the purchase price allocations for the acquisitions of 2020

2 In constant currencies

3 Acc. to customers' location

4 Adjusted for extraordinary items

5 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, and based on the normalized financial result and tax rate


A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686


Cision View original content:

SOURCE Sartorius AG

Related Businesses
- - Customer

Copyright © 2021 by (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by, Inc. Except as expressly permitted by, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable., Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Saturday, July 31, 2021